Can Jakafi hit $3B? Incyte says so—and new meds are coming, too by Eric Sagonowsky Thursday, February 13, 2020 Incyte's now aiming for $3 billion in peak Jakafi sales—and $2 billion in 2020—but it's also prepping for a potential pemigatinib rollout this year.
Jakafi-maker Incyte rolls TV ads to boost polycythemia vera awareness by Beth Snyder Bulik Wednesday, July 24, 2019 Incyte's latest push aims to help polycythemia vera patients, and it's starting out by targeting five regions where polycythemia vera is most common.
Incyte's faithful Jakafi ready to roll with brand-new indication by Angus Liu Wednesday, May 29, 2019 Incyte's bone marrow drug Jakafi has been pitching in blockbuster-level sales, and now it has a new approval that could give it another boost.
Incyte hands CEO Hoppenot a 36% pay hike despite R&D setbacks by Arlene Weintraub Tuesday, March 20, 2018 Incyte CEO Hervé Hoppenot scored a big pay raise in 2017, even after the FDA rebuffed the highly anticipated RA drug it's developing with Eli Lilly.
Drama and diagnosis on soap opera set puts Incyte in hot seat by Beth Snyder Bulik Monday, May 22, 2017 Soap operas often include medical mysteries and miracles, but some doctors are concerned about Incyte's connection to General Hospital's latest drama.
13. Jakafi by Phil Taylor Jakafi's inclusion in the top 15 list may be something of a surprise, given the news earlier this year that Incyte was pulling the plug on the drug for solid tumors after two failed trials in prostate and colorectal cancer.
